222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

24 trials found

diseases per page:

Showing 1 to 10 of 24 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05532111 (ClinicalTrials.gov)	September 1, 2022	1/9/2022	Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial	Efficacy and Safety of Rituximab Combined With Tacrolimus in the Treatment of Intermediate-to-high R ...	Efficacy and Safety	Drug: Rituximab combined with tacrolimus induction + rituximab maintenance;Drug: Rituximab combined wi ...	RenJi Hospital	NULL	Not yet recruiting	18 Years	75 Years	All	60	N/A	NULL
2	ChiCTR2200059658	2022-05-01	2022-05-05	Establishment and validation of the prediction model of membranous nephropathy	Establishment and validation of the prediction model of membranous nephropathy	membranous nephropathy	Cyclophosphamidebased initial treatment:Cyclophosphamidebased treatment;Cyclosporinebased initial tr ...	People’s Hospital of Guangxi Zhuang Autonomous Region	NULL	Recruiting	14	80	Both	Cyclophosphamide based initial treatment:400;Cyclosporine based initial treatment:400;		China
3	ChiCTR2200057381	2022-03-01	2022-03-10	Efficacy and safety of low-dose rituximab in the treatment of membranous nephropathy	Efficacy and safety of low-dose rituximab in the treatment of membranous nephropathy	membranous nephropathy	rituximab group:rituximab;control:hormone combined with cyclophosphamide;	Peking University Third Hospital	NULL	Pending	18	80	Both	rituximab group:68;control:135;	N/A	China
4	ChiCTR2100048518	2021-10-31	2021-07-09	A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequent ...	A prospective, multi-center, real-world clinical trial of tacrolimus combined with belimumab sequent ...	idiopathic membranous nephropathy	low-dose multi-target group:No;tacrolimuscombined with belimumabsequential group:No;intravenous cycl ...	The Second Affiliated Hospital of Xi'an Jiaotong University	NULL	Pending	18	70	Both	low-dose multi-target group:100;tacrolimus combined with belimumab sequential group:100;intravenous cyclophosphamide pulse group:100;		China
5	ChiCTR2100049205	2021-08-01	2021-07-25	A prospective randomized controlled multicenter clinical study on the treatment strategy of primary ...	A prospective randomized controlled multicenter clinical study on the treatment strategy of primary ...	Membranous nephropathy	Group B:Cyclophosphamidecombined with glucocorticoids;Group C:Low-dose Cyclophosphamide, glucocortic ...	Shanghai Dongfang Hospital	NULL	Recruiting	18	75	Both	Group B:30;Group C:30;Group A:30;		China
6	NCT04745728 (ClinicalTrials.gov)	April 14, 2021	4/2/2021	Different Immunosuppressive Treatment in iMN	Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort	Idiopathic Membranous Nephropathy	Drug: Prednisone;Drug: Cyclophosphamide;Drug: Rituximab	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	80 Years	All	200	Phase 3	China
7	ChiCTR2000033766	2020-07-01	2020-06-11	Diagnostic value of serum C4d, PLA2R, THSD7A antibody in idiopathic membranous nephropathy and analy ...	Diagnostic value of serum C4d, PLA2R, THSD7A antibody in idiopathic membranous nephropathy and analy ...	Membranous nephropathy	1:Prednisone + cyclophosphamide;2:Prednisone + Tacrolimus;	The First Affiliated Hospital of Bengbu Medical College	NULL	Pending	17	70	Both	1:30;2:30;	Phase 4	China
8	ChiCTR1800019833	2019-01-01	2018-12-02	Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophospha ...	Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophospha ...	Idiopathic Membranous Nephropathy	PLA2R???:Cyclophosphamidecombined with hormone therapy ;PLA2R positive Group:Cyclophosphamidecombine ...	Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University	NULL	Pending	18	85	Male	PLA2R???:30;PLA2R positive Group:30;		China
9	ChiCTR1800016140	2018-07-01	2018-05-14	Comparison of the efficacy and safety of tacrolimus and glucocorticoid combined with cyclophosphamid ...	A randomized controlled trial for the treatment of primary membranous nephropathy	primary membranous nephropathy	Tacrolimusgroup:Tacrolimus0.05-0.1mg/kg/d;Cyclophosphamidegroup:CTX 750mg/m2 ivgtt q2w for 8 weeks, ...	Sichuan Provincial People's Hospital	NULL	Pending	18	65	Both	Tacrolimus group:45;Cyclophosphamide group:45;		China
10	NCT05679336 (ClinicalTrials.gov)	May 1, 2018	28/11/2022	Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy	Rituximab, Cyclophosphamide, and Corticosteroids at Low Cumulative Doses to Induce Remission in Prim ...	Membranous Nephropathy - PLA2R Induced	Drug: Rituximab , Cyclophosphamide, and Corticosteroids	St. Petersburg State Pavlov Medical University	NULL	Recruiting	18 Years	75 Years	All	40	N/A	Russian Federation

First Previous1 2 3Next Last